Article Text

OP0281 Kawasaki Disease in France: Incomplete Forms Are the Most Frequent and Are Associated with High Frequency of Cardiac Complications
  1. I. Koné paut1,
  2. M. Darce Bello1,
  3. K. Brochard2,
  4. E. Merlin3,
  5. E. Launay4,
  6. P. Lechevalier5,
  7. F. Uettwiller6,
  8. P. Brosset7,
  9. F. Boralevi8,
  10. S. Di-filippo9,
  11. V. Gajdos10,
  12. F. Madhi11,
  13. E. Bosdure12,
  14. C. Laure13,
  15. A. Arnoux13,
  16. M. Piram1
  17. on behalf of French KD Group
  1. 1Pediatric Rheumatology, Bicêtre Hospital, Le Kremlin-Bicêtre
  2. 2Pediatric Nephrology, Purpan Hospital, Toulouse
  3. 3Paediatrics, Clermont Ferrand Hospital, Clermont Ferrand
  4. 4Paediatrics, Nantes Hospital, Nantes
  5. 5Paediatrics, Robert Debré Hospital, Paris
  6. 6Paediatrics, Clocheville Hospital, Tours
  7. 7Paediatrics, Limoges Hospital, Limoges
  8. 8Pediatric Dermatology, Pellegrin Hospital, Bordeaux
  9. 9Pediatric Cardiology, Cardiology Hospital, Lyon
  10. 10Paediatrics, Antoine Beclère Hospital, Clamart
  11. 11Paediatrics, Créteil Hospital, Créteil
  12. 12Paediatrics, La Timone, Marseille
  13. 13Clinical Research, Bicêtre Hospital, Le Kremlin-Bicêtre, France


Background KD is the main vasculitis affecting children before 5 years and the leading cause of acquired heart disease in childhood. The epidemiologic characteristics of KD are few reported in Europe and especially in France within a population from different ethnic backgrounds. Even IVIG is still the standard treatment of KD; the management of patients at risk for cardiac complications may change toward reinforced (and new) therapeutic approaches.

Objectives Kawanet is a clinical and biological data repository aimed to define the epidemiological characteristics of KD, in France. Kawanet will compare clinical characteristics between distinct ethnic backgrounds and will define risk factors for resistance to standard treatment (IVIG) and for cardiac complications

Methods Targeted institutional physicians received information on a national registry for KD. All patients suspected with KD and seen since January 2011 were eligible to enter the study. An eCRF was implemented in a web secured database (CLEANWeb). IRB approval and authorization for data storage were obtained.

Results 419 cases were entered into the registry and complete information was available for 351 of them, in January 2014. Patients (57% males/43% females) were enrolled by 77 physicians from 52 centres: they originated from 5 main ethnical backgrounds: 67% European Caucasian, 15% afro-Caribbean, 13% Eastern Caucasian or North African, 4% Asian and 1% of mixed ancestry. The median age at diagnosis was 2.4y (3m-26y). A family history of KD was present in 5 patients. The clinical symptoms were (%): conjunctivitis 85, cheilitis 83, diffuse exanthema 74, fever ≥5 days 63, oral erythema 61, modification of the extremities 57, cervical adenopathy 49, oedema 47, raspberry tongue 45, desquamation 40, seat erythema 26 and perineal desquamation 17. Cardiac complications were reported in 186/328 patients (42%): coronary dilatation 28%, pericarditis 17%, coronary aneurysm 4%, and myocarditis 3%. At diagnosis of 351 patients: 135 had complete KD according to the AAC definition, 56 were incomplete, 118 doubtful and 42 not classified. 327/331 (99%) patients received IVIG, 20% (n=64) required 2 courses, and 5 patients 3 courses. 11% required steroids, 93% received Aspirin and 1 Anti-TNF. The mean delay between fever onset and treatment was 6 days.

Conclusions The awareness on KD appears very high in France, even the completed forms are relatively rare (38%). The rate of coronary abnormalities was elevated, in comparison to other series even though 1/3 of patients receiving IVIG had doubtful diagnosis of KD. The IVIG resistance rate was 20%. Factors associated with IVIG resistance in our population are currently analysed

Acknowledgements To the French KD study group

Supported by a grant from the French ministry of health: PHRCN2009

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3534

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.